A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease

Research output: Contribution to journalJournal articleResearchpeer-review

  • Satish Keshav
  • Tomáš Vaňásek
  • Yaron Niv
  • Robert Petryka
  • Stephanie Howaldt
  • Mauro Bafutto
  • István Rácz
  • David Hetzel
  • Nielsen, Ole Haagen
  • Séverine Vermeire
  • Walter Reinisch
  • Per Karlén
  • Stefan Schreiber
  • Thomas J Schall
  • Pirow Bekker
Original languageEnglish
Article numbere60094
JournalP L o S One
Issue number3
Number of pages12
Publication statusPublished - 2013

ID: 120017036